IMRX vs RARE · $124.2M cap vs rev $350.0M
Immuneering Corp (IMRX) versus Ultragenyx (RARE) — a side-by-side from cached financials, not a winner call.
Immuneering Corp (IMRX) is a biotechnology company listed on US.
Ultragenyx (RARE) is a biotechnology company listed on US.
IMRX does not have a complete income-statement cache yet.
Latest reported RARE revenue for 2026-06-30 was $350.0M. Net income was -$277.0M. RARE currently screens at market cap $2.79B.
IMRX currently screens at market cap $124.2M. RARE currently screens at market cap $2.79B.
Not investment advice. Open the IMRX and RARE stock pages for the full models.
Not investment advice.